Browse the evidence

Long-term maintenance of cardiorespiratory fitness (CRF) improves insulin sensitivity in men with visceral obesity, even when visceral adipose tissue (VAT) rebounds.

Focus on maintaining your aerobic fitness (cardiorespiratory fitness) rather than obsessing over small fluctuations in body fat. If you maintain your fitness level, your body's ability to handle insulin remains high, even if you regain some visceral fat. Prioritize consistent physical activity over strict weight maintenance.

Reductions in intramuscular fat (specifically core and psoas low-attenuation muscle area) are associated with improved insulin resistance, independent of visceral fat changes.

Exercise helps reduce fat stored within muscles (intramuscular fat), which directly improves how your body uses insulin. This benefit occurs even if you don't lose all your belly fat.

Health and wellness coaching (HWC) interventions for obesity and Type 2 Diabetes (T2D) demonstrate beneficial clinical findings, but current randomized controlled trials (RCTs) exhibit moderate design quality (average 56.7% score), with T2D studies showing significantly better intervention design fidelity than obesity studies.

Health coaching works for obesity and diabetes, but the quality of the coaching matters more than just the number of sessions. Look for coaches who are certified (NBHWC) and use structured behavior change strategies. For obesity, ensure the program is long-term (over 4 months) and includes frequent sessions, as these studies showed lower design quality and potentially less effective delivery compared to diabetes programs.

Noninvasive tests (FIB-4, ELF, MRE) are recommended for screening and risk stratification of MASLD, with FIB-4 as the first-line assessment due to its simplicity and cost-effectiveness.

If you have metabolic risk factors like obesity or type 2 diabetes, ask your doctor for a FIB-4 score. It is a simple, low-cost calculation using age, AST, ALT, and platelet count that helps identify liver fibrosis risk early.

Endoscopic bariatric therapies (EBMTs), including intragastric balloons and endoscopic sleeve gastroplasty, provide significant weight loss and metabolic improvements as minimally invasive alternatives to surgery, though they are associated with specific adverse events and potential weight regain.

Endoscopic bariatric therapies are a viable, minimally invasive option for weight loss, particularly for those who cannot or will not undergo surgery. Procedures like intragastric balloons and endoscopic sleeve gastroplasty can achieve significant weight loss (25-60% excess weight loss) when combined with lifestyle changes. However, they are not risk-free, with potential side effects ranging from nausea to rare serious complications. Patients should discuss their BMI, health status, and preference for invasiveness with a specialist to determine if an EBMT is appropriate, keeping in mind that some devices are temporary and may require combination with medication or surgery for long-term success.

GLP-1 receptor agonist therapy induces lean mass loss proportional to fat loss (approx. 25% of total weight loss), which is a physiological response to caloric restriction rather than a unique pathological catabolic effect of the drug.

If you are taking a GLP-1 drug like Semaglutide, expect to lose about 25% of your total weight as muscle. This is normal and similar to losing weight through diet alone. To protect your muscle, prioritize resistance training and eat 1.2-1.6g of protein per kg of body weight daily.

Increasing primary care provider (PCP) referral rates for weight loss surgery (WLS) significantly increases the volume of WLS procedures performed, with simulated interventions predicting up to a 24.1% increase in surgeries over 3 years.

If you are eligible for weight loss surgery, your primary care doctor's willingness to refer you is the biggest hurdle. This study suggests that simply encouraging your PCP to refer you to a specialist (endocrinologist or surgeon) significantly increases your chances of eventually having the surgery. If your PCP is hesitant, ask for a referral to a subspecialty obesity clinic, as this is a common stepping stone to surgery.

Preservation of skeletal muscle mass is a critical consideration in obesity treatment with second-generation medications, and new drugs (e.g., bimagrumab) are being developed to block muscle loss.

When you lose weight, you might lose some muscle. This is a concern, especially for older adults. New treatments are being developed to help preserve muscle mass while you lose fat. Talk to your doctor about strategies to maintain muscle strength during weight loss.

Dual GLP-1/GIP receptor agonism (e.g., tirzepatide) produces synergistic body weight loss compared to selective GLP-1 receptor agonists, a mechanism dependent on the interaction of signals in neurotensin-expressing neurons (Nts CeA) within the central amygdala.

Dual GLP-1/GIP medications (like tirzepatide) are more effective for weight loss than GLP-1-only drugs because they activate a specific brain pathway (neurotensin neurons in the central amygdala) that GLP-1 drugs alone do not fully engage. This biological synergy is the reason for their superior efficacy, not just better stomach tolerance.

Weekly subcutaneous semaglutide (2.4 mg) significantly improves functional capacity and reduces heart failure hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity.

If you have heart failure with preserved ejection fraction (HFpEF) and obesity, ask your doctor about weekly semaglutide injections (2.4 mg). This treatment has been shown to significantly improve your ability to perform daily activities, reduce your body weight, and lower your risk of being hospitalized for heart failure.

Semaglutide 2.4 mg administered once weekly for 68 weeks significantly improves health-related quality of life (HRQoL) utility scores compared to placebo in adults with overweight or obesity.

If you are an adult with overweight or obesity, taking 2.4 mg of semaglutide once weekly for about 16 months, alongside diet and exercise changes, is likely to significantly improve your daily health quality of life compared to placebo. This benefit is particularly pronounced if you have a higher BMI (over 40) or specific conditions like knee osteoarthritis or sleep apnea.

Waist circumference (WC) is a critical, 'vital' parameter for assessing cardiovascular risk in obesity, providing prognostic information that BMI alone fails to capture, particularly regarding visceral adipose tissue (VAT).

Ask your doctor to measure your waist circumference at every visit. It is a key indicator of heart disease risk that weight alone cannot show, especially if you have a 'normal' weight but carry fat around your midsection.

SGLT2 inhibitors reduce body weight and blood pressure, contributing to their overall benefit in CRM syndrome.

SGLT2 inhibitors typically lead to a modest weight loss of 1.5-3 kg over 1-2 years, which is a beneficial side effect for managing metabolic syndrome.

Bodybuilders primarily rely on fitness coaches and registered dietitians for information regarding dietary supplements, rather than independent medical advice or rigorous scientific literature.

When choosing supplements, prioritize advice from registered dietitians or nutritionists over fitness coaches, as coaches may lack specific nutritional expertise. This reduces the risk of misinformation and adverse effects.

The most commonly consumed dietary supplements among bodybuilders are Vitamin C, Vitamin D, and Whey Protein.

If you are a bodybuilder, you are likely taking Vitamin C, Vitamin D, and Whey Protein. Ensure your dosage of these is appropriate for your body weight and health status, and do not exceed recommended daily allowances without medical supervision.

Digital behavioral interventions are as effective as nondigital behavioral interventions for reducing overall cardiovascular risk factors, with no significant difference found across 11 key metrics.

You can use digital tools (apps, wearables, web platforms) to manage heart health risks just as effectively as traditional face-to-face programs or printed materials. The key is consistency and using evidence-based behavioral strategies, regardless of the delivery method.

Higher intake of red or processed meat is associated with increased all-cause, cardiovascular, and cancer-related mortality, but this association is largely explained by confounding factors such as smoking, obesity, and alcohol consumption rather than the protein itself.

While high intake of red and processed meats is linked to higher mortality, this risk appears to be driven largely by associated lifestyle factors like smoking, obesity, and alcohol use rather than the protein itself. Focus on maintaining a healthy weight, avoiding smoking, and limiting alcohol, as these factors likely explain the observed risks more than the meat consumption alone.

Higher intake of poultry, milk, and cheese is associated with reduced mortality risk in unadjusted models, but this protective effect is also substantially attenuated after adjusting for lifestyle confounders.

While high intake of poultry, milk, and cheese is linked to lower mortality in initial analyses, this benefit appears to be driven largely by associated lifestyle factors like not smoking, healthy weight, and moderate alcohol use rather than the food itself. Focus on maintaining a healthy lifestyle, as these factors likely explain the observed benefits more than the specific foods alone.

A longitudinal dietary pattern characterized by decreasing low-carbohydrate intake and increasing high-fat intake is associated with a lower risk of all-cause mortality in males, despite being associated with a higher risk of obesity.

For men in this demographic, shifting dietary habits to reduce carbohydrate intake (specifically from a low baseline) while allowing fat intake to increase over time is associated with a lower risk of death, though it comes with a higher risk of obesity. This suggests that for long-term survival, macronutrient quality and trajectory may matter more than total fat avoidance, but weight management remains a challenge.

A longitudinal dietary pattern characterized by decreasing very high-carbohydrate intake and a U-shape protein trajectory is associated with a significantly higher risk of diabetes in males.

For men, starting with a very high carbohydrate diet, even if you reduce it over time, may increase your risk of developing diabetes, especially if your protein intake follows a U-shaped pattern (high, then lower, then higher). This suggests that managing initial carbohydrate load and protein quality/timing is crucial for diabetes prevention.

A longitudinal dietary pattern characterized by decreasing very high-carbohydrate intake and moderate protein intake is associated with a higher risk of diabetes in females.

For women, starting with a very high carbohydrate diet, even if you reduce it over time, may increase your risk of developing diabetes, even if your protein intake remains moderate. This suggests that managing initial carbohydrate load is crucial for diabetes prevention in women.

GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide) cause significant loss of lean muscle mass (up to 40% of total weight loss), which contributes to reduced resting energy expenditure and increased risk of sarcopenia and weight regain.

If you are taking GLP-1 drugs, expect to lose some muscle along with fat. To protect your metabolism and strength, you must prioritize resistance training and adequate protein intake during your weight loss journey.

Skeletal muscle loss during pharmacologically induced weight loss is clinically significant because excessive SMM loss reduces resting energy expenditure (REE), making weight maintenance more difficult.

To maintain weight loss, preserving muscle is critical because muscle burns calories at rest. If you lose too much muscle, your metabolism slows down, making it harder to stay lean. Ensure your weight loss plan includes adequate protein and resistance training to protect muscle mass.

Dietary protein intake and resistance exercise can attenuate fat-free mass and skeletal muscle loss during caloric restriction, but may not completely abrogate it.

To minimize muscle loss while dieting, aim for higher protein intake (potentially 2-3x the standard recommendation) and incorporate resistance training. Note that even with these efforts, some muscle loss is likely unavoidable during significant weight reduction.